Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Top Indices
DJI
Nasdaq Composite
SPX
My Portfolio
AbbVie
(NY:
ABBV
)
193.47
-0.15 (-0.08%)
Official Closing Price
Updated: 4:10 PM EDT, Sep 20, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about AbbVie
< Previous
1
2
3
4
5
6
7
8
9
...
67
68
Next >
Unpacking the Latest Options Trading Trends in AbbVie
May 14, 2024
Via
Benzinga
3 Magnificent Stocks That Are Passive Income Machines
May 14, 2024
These three companies have track records that should please investors.
Via
The Motley Fool
What Is the Dividend Payout for AbbVie Stock?
May 13, 2024
The pharmaceutical company isn't just a quality healthcare holding. It's a compelling income investment as well.
Via
The Motley Fool
Healthcare And Biotech Investing 101: What You Need To Know.
May 13, 2024
Healthcare as a sector represents only about 12% of the S&P 500. If you want to overweight healthcare as a sector you need to add equities. Healthcare is usually a defensive sector because of...
Via
Talk Markets
Topics
Stocks
Exposures
US Equities
Earn $1000 Every Month From These 3 Stocks
May 11, 2024
All 3 companies pay growing dividends.
Via
The Motley Fool
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever.
May 11, 2024
These pharmaceutical companies are top-notch dividend growth stocks for the future.
Via
The Motley Fool
(ABBV) - Analyzing AbbVie's Short Interest
May 10, 2024
Via
Benzinga
3 Reasons to Buy AbbVie Stock on the Dip
May 05, 2024
A little patience with the drugmaker should pay off.
Via
The Motley Fool
$1000 Invested In This Stock 10 Years Ago Would Be Worth $3,100 Today
May 02, 2024
Via
Benzinga
3 Rock-Solid Dividend Stocks That Are Ideal for Retirees
May 10, 2024
These are low-risk stocks with high yields.
Via
The Motley Fool
Biotech Breakthroughs: 7 Stocks Driving the Next Wave in Healthcare
May 07, 2024
Investors concerned about broader market undulations may want to consider the resilience narrative of these biotech stocks to buy.
Via
InvestorPlace
AbbVie Tracking for New Highs in 2024
May 07, 2024
Future Dividend King AbbVie is tracking for new highs as the shift away from Humira-based business gains momentum with new treatments and acquisitions.
Via
MarketBeat
Topics
Earnings
Exposures
Financial
3 Biotech Stocks to Double Your Money in the Next 24 Months
May 06, 2024
The biotech sector offers significant potential for growth. These 3 biotech stocks to double your money are noteworthy candidates.
Via
InvestorPlace
MarketBeat Week in Review – 4/29 - 5/3
May 04, 2024
Apple, Amgen, and a weak jobs report helped move the market higher as investors temporarily looked past the possibility of no interest rate cuts in 2024
Via
MarketBeat
Topics
Economy
Stocks
Exposures
Interest Rates
US Equities
Peeling Back The Layers: Exploring AbbVie Through Analyst Insights
April 29, 2024
Via
Benzinga
Will Earnings Cheer Continue To Buoy Markets? Apple, Amazon, Pfizer, Coinbase Lead Flurry Of Q1 Reports This Week
April 29, 2024
With the earnings season now halfway through, the percentage of S&P 500 companies reporting positive earnings surprises and the magnitude of earnings surprises were above their 10-year averages.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
7 Safe Haven Stocks That Can Withstand the Market’s Worst Meltdowns
April 30, 2024
Safe haven stocks offer stability even during market fall in communication, financials, healthcare, energy and consumer staples.
Via
InvestorPlace
Analyst Sentiment, Revenue Growth Will Lead AbbVie Stock Higher
April 30, 2024
After falling nearly 6% based on concerns about Humira sales, AbbVie stock is recovering, and bullish analyst sentiment is likely to push the stock higher
Via
MarketBeat
Inflation-Proof Fortunes: 7 Dividend Aristocrats to Keep Your Wealth Growing
April 30, 2024
These dividend aristocrat stocks can protect tired consumers from persistent inflation through dividends that outpace recent spikes.
Via
InvestorPlace
Topics
Economy
Exposures
Interest Rates
AbbVie Outlook: Why Humira Biosimilars Won't Undo A Projected $73 Billion In Sales
April 29, 2024
The company is projected to bring in increasing sales through at least 2029.
Via
Investor's Business Daily
Better Dividend Stock: AbbVie or Johnson & Johnson?
April 28, 2024
One thing is for sure: Dividend seekers can't go wrong with either.
Via
The Motley Fool
3 Dividend Stocks to Buy and Hold for the Next Decade
April 27, 2024
You'll get dividends and more with these great stocks.
Via
The Motley Fool
Why AbbVie Stock Stumbled Today Despite the Earnings Beat
April 26, 2024
Investors are struggling to see past the end of Humira's dominance.
Via
The Motley Fool
AbbVie (ABBV) Q1 2024 Earnings Call Transcript
April 26, 2024
ABBV earnings call for the period ending March 31, 2024.
Via
The Motley Fool
Topics
Earnings
Exposures
Financial
Arthritis Patients - Cigna's Evernorth To Offer Humira Biosimilar At No Out-of-Pocket Cost
April 26, 2024
Evernorth Health Services' initiative to offer Humira biosimilar with $0 out-of-pocket costs for patients. Save an average of $3,500 yearly.
Via
Benzinga
Tech Stocks Rebound As Magnificent 7 Roar On Strong Earnings, Energy Giants Tumble: What's Driving Markets Friday?
April 26, 2024
Strong earnings reports from Alphabet Inc. (NASDAQ:GOOGL) and Microsoft Corp. (NASDAQ:MSFT) have restored positive sentiment in the market, sweeping away fears of increasing risks of stagflation that...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
ABBV Stock Earnings: AbbVie Beats EPS, Beats Revenue for Q1 2024
April 26, 2024
ABBV stock results show that AbbVie beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
Ex-Humira Growth Platform Drives AbbVie's Q1 Performance, Drugmaker Lifts Annual Profit Outlook
April 26, 2024
AbbVie impresses with Q1 results: EPS beats at $2.31 (-6.1% Y/Y), net revenue exceeds at $12.31 billion (+0.7%). Notable: Immunology sales, Humira vs. biosimilars, oncology gains.
Via
Benzinga
AbbVie Beats First-Quarter Views As Skyrizi Looks To Take Humira's Title
April 26, 2024
Skyrizi brought in $2.01 billion in sales, just barely trailing the $2.27 billion generated by the struggling Humira.
Via
Investor's Business Daily
Wall Street Futures Ride High On Microsoft, Alphabet Cheer, But Will Inflation Data Burst The Bubble? Why This Analyst Thinks Bull Run Isn't Over Yet
April 26, 2024
Tech earnings could come to the market’s rescue as traders remain jittery about the outcome of key inflation data due on Friday.
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
< Previous
1
2
3
4
5
6
7
8
9
...
67
68
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.